SPRINGFIELD, NJ, Evergreen Theragnostics, a clinical stage contract development and manufacturing organization, announced the completion of a $15M Series B.
Evergreen Theragnostics, a clinical stage contract development and manufacturing organization (CDMO) developing radiopharmaceuticals for cancer therapy, announced the completion of a $15M Series B capital raise. The round was primarily subscribed by existing shareholders exercising their rights of first refusal.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
